(NASDAQ: IBRX) Immunitybio's forecast annual revenue growth rate of 61.3% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 31.44%, and it is also forecast to beat the US market's average forecast revenue growth rate of 12.15%.
Immunitybio's revenue in 2026 is $182,572,000.On average, 6 Wall Street analysts forecast IBRX's revenue for 2026 to be $217,829,026,707, with the lowest IBRX revenue forecast at $207,158,851,195, and the highest IBRX revenue forecast at $226,648,144,853. On average, 6 Wall Street analysts forecast IBRX's revenue for 2027 to be $389,456,087,065, with the lowest IBRX revenue forecast at $361,498,737,866, and the highest IBRX revenue forecast at $424,583,623,995.
In 2028, IBRX is forecast to generate $891,358,590,045 in revenue, with the lowest revenue forecast at $848,848,100,168 and the highest revenue forecast at $925,677,619,160.